|Day Low/High||0.01 / 0.01|
|52 Wk Low/High||0.01 / 127.72|
OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings"
Company Plans to file 2016 Fourth Quarter and Year End Financial Results by March 30, 2017
Single-Center Retrospective Data Also Demonstrate Therapy Extends Progression-Free Survival by 9 Months
Retrospective Analysis of Outcomes with Investigational Melphalan/HDS and Commercial CHEMOSAT® Projects Median Overall Survival to be 657 Days; 1,207 Days for Responders
Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced the pricing of an underwritten public offering of 425,000...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.